AUG is unlocking rare disease drug access by reformulating off-patent drugs that already work for patients who can't get them

Summary

Jennifer Lynn's company AUG is built on a straightforward premise: drugs that already work for rare disease patients often never reach them, not because the science failed but because the logistics did. A physician tries a compound on one or two patients, writes up encouraging results, and the rest of the patient population gets nothing. AUG's job is to close that gap.

The mechanism is reformulation. Many of these effective drugs exist in the wrong delivery format — a dose level too high for practical use, an injection when patients need an eye drop, a formulation that isn't stable enough to distribute. AUG takes an existing compound and engineers the version that actually works for the target population. The safety profile is usually already established, which compresses the development risk considerably.

To avoid the licensing friction that comes with in-patent assets — major pharma, Lynn says, defaults to demanding large upfront cash regardless of indication — AUG focuses on off-patent drugs. These are compounds whose commercial life in large indications like autoimmune disease has already run its course, their patents expired, their prices low. AUG adds the rare-disease-specific formulation layer on top.

Regulatory leverage

Rare disease is structurally easier to navigate at the FDA than crowded therapeutic areas like breast cancer, where new entrants must run multi-year trials against drugs that already work. In rare disease, the comparison is often placebo or historical controls, because there is frequently no approved treatment. That compresses timelines and costs.

Lynn identifies the antibody and biologic space as the current low-hanging fruit. The FDA recently issued guidance allowing certain biologic drugs to skip extensive animal testing if human safety data already exists, which can cut a meaningful portion of preclinical work for compounds with established profiles.

Pricing dynamics

Rare disease pricing holds up better than it might appear. Payers push back hardest on drugs for large indications — Alzheimer's or longevity treatments — where broad adoption would put hundreds of billions of dollars on insurers' books. A rare disease drug priced at $100,000 per year across 10,000 patients spreads thinly across the U.S. payer landscape, making reimbursement conversations, in Lynn's telling, relatively smooth.

Longevity as the moonshot

Outside AUG's core focus, Lynn flags longevity as the most compelling adjacent opportunity: a drug that genuinely slows aging would enter a market where every person on earth is a potential patient. First-mover advantage in that category would be extraordinary, though the science remains unsettled.